For the patient who presents with a new diagnosis of SLE, or for the one who has a flare in previously established disease, the immediate need is to achieve control of the inflammatory process.

The results from a retrospective study of 50 patients with systemic lupus erythematosus (SLE) and osteonecrosis of the femoral head suggest that free vascularized fibular grafting offers a viable ...

Prophylactic valaciclovir was effective and prevented herpes zoster in patients with systemic lupus erythematosus receiving ...

In the Phase 2b CARE study, the investigational drug, cenerimod, demonstrated safe and effective results for treatment of ...

Objectives SLE is a multifaceted autoimmune disorder with a complex pathogenesis involving genetic, environmental and ...

Two recent, uncontrolled studies have shown that B-cell depletion with rituximab, and repeated B-cell depletion with rituximab, are effective in treating systemic lupus erythematosus (SLE ...

Systemic lupus erythematosus (SLE) is an autoimmune disease that causes skin rash and can affect multiple organs including the kidneys, joints and the brain. The disease was in the news recently ...

Bullous systemic lupus erythematosus (BSLE) is a rare presentation occurring in people with systemic lupus erythematosus (SLE). It causes blisters on the skin and may affect the internal organs.

Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been ...

In a new study, the drug, deucravacitinib, proved to be a safe and more effective treatment for cutaneous lupus erythematosus disease (CLE, lupus skin disease) than two other commonly used therapies, ...

Three lupus patients in the UK have received ‘groundbreaking’ new treatment which could end the need for lifelong drugs. A ...